Ana Paula Ferreira Costa

Ana Paula Ferreira Costa

Auto-generated profile, based on publicly available information

Ana Paula Ferreira Costa

Universidade Federal do Rio Grande do Norte, Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
JLJuliana Lírio
Juliana Lírio
PGPaulo Cesar Giraldo
Paulo Cesar Giraldo
RARose Luce Amaral
Rose Luce Amaral
ASAyane Cristine Alves Sarmento
Ayane Cristine Alves Sarmento
ACAna Paula Ferreira Costa
Ana Paula Ferreira Costa
AGAna Katherine Da Silveira Gonçalves
Ana Katherine Da Silveira Gonçalves
Introduction Vulvovaginal candidiasis (VVC) is frequent in women worldwide and usually responds rapidly to topical or oral antifungal therapy. However, some women develop recurrent vulvovaginal candidiasis (RVVC), which is arbitrarily defined as four or more episodes every year. RVVC is a debilitating, long-term condition that can severely affect the quality of life of women. Most VVC is diagnosed and treated empirically and women frequently self-treat with over-the-counter medications that could contribute to an increase in the antifungal resistance. The effective treatment of RVVC has been a challenge in daily clinical practice. This review aims to assess the efficacy of antifungal agents administered orally or intravaginally for the treatment of RVVC, in order to define clinical practices that will impact on the reduction of the morbidity and antifungal resistance. Methods and analysis A comprehensive search of the following databases will be carried out: PubMed, Embase, Scopus, Web of Science, Scientific Electronic Library Online (SciELO), the Cochrane Central Register of Controlled Trials (CENTRAL), Biblioteca Virtual em Saúde (Virtual Health Library)/Biblioteca Regional de Medicina (Regional Library of Medicine) (BVS/BIREME), Cumulative Index to Nursing and Allied Health Literature (CINAHL) and in the clinical trials databases (www.trialscentral.org; www.controlled-trials.com; www.clinicaltrials.gov). The risk of bias will be assessed according to the Cochrane Risk of Bias tool. We will perform data synthesis using the Review Manager (RevMan) software V.5.2.3. To assess heterogeneity, we will compute the I2 statistic. Ethics and dissemination This study will be a review of published data and it is not necessary to obtain ethical approval. Findings of this systematic review will be published in a peer-reviewed journal. Trial registration number CRD42018093817

24 July 2017 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
ACAna Paula Ferreira Costa
Ana Paula Ferreira Costa
Ricardo CobucciRicardo Cobucci
Ricardo Cobucci
JSJanine Medeiros da Silva
Janine Medeiros da Silva
PLPaulo Henrique da Costa Lima
Paulo Henrique da Costa Lima
PGPaulo César Giraldo
Paulo César Giraldo
AGAna Katherine Da Silveira Gonçalves
Ana Katherine Da Silveira Gonçalves
Vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries for approximately 10 years. In order to increase the protection of the vaccines, a 9-valent vaccine (HPV9) was developed, which provides protection against nine types of the virus. Studies evaluating its safety are rare. Thus, we performed a meta-analysis of three clinical trials assessing adverse effects on women randomly vaccinated with HPV9 or tetravalent vaccine (HPV4), with the objective of analyzing whether the HPV9 is as safe as HPV4. An electronic data search was performed through the PubMed, Embase, Scopus, Web of Science, and SciELO databases. The studies selected 27,465 women who received one of the two vaccines. Pain (OR 1.72; 95% CI 1.62–1.82) and erythema (OR 1.29; 95% CI 1.21–1.36) occurred significantly more in the HPV9 group. However, there was no significant difference between the groups for the following adverse effects: headache (OR 1.07; 95% CI 0.99–1.15), dizziness (OR 1.09; 95% CI 0.93–1.27), and fatigue (OR 1.09; 95% CI 0.91–1.30), and the occurrence of serious events related to vaccination was similarly rare among those vaccinated. Therefore, our findings demonstrate that HPV9 in female patients is as safe as the tetravalent vaccine.

25 April 2019 in International Journal of Gynecology & Obstetrics
Verified
Journal Article
Closed access
PDF file
KRKarinne F. Rebouças
Karinne F. Rebouças
JJJOSE Eleutério Junior
JOSE Eleutério Junior
RPRaquel C. Peixoto
Raquel C. Peixoto
ACAna Paula F. Costa
Ana Paula F. Costa
Ricardo CobucciRicardo Cobucci
Ricardo Cobucci
JJJosé E Junior
José E Junior

1 January 2023 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
IXIvete Matias Xavier
Ivete Matias Xavier
ASAna Carolina Zimmermann Simões
Ana Carolina Zimmermann Simões
RORonnier de Oliveira
Ronnier de Oliveira
YBYasha Emerenciano Barros
Yasha Emerenciano Barros
ASAyane Cristine Alves Sarmento
Ayane Cristine Alves Sarmento
AGAna Katherine Da Silveira Gonçalves
Ana Katherine Da Silveira Gonçalves
The objective of this study was to determine adverse maternal and perinatal outcomes in pregnant women with hypertensive disorders of pregnancy.

3 June 2024 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
LPLisieux de Lourdes Martins Nóbrega Pessoa
Lisieux de Lourdes Martins Nóbrega Pessoa
Amaxsell Thiago Barros de SouzaAmaxsell Thiago Barros de Souza
Amaxsell Thiago Barros de Souza
ASAyane Cristine Alves Sarmento
Ayane Cristine Alves Sarmento
ACAna Paula Ferreira Costa
Ana Paula Ferreira Costa
ISIsis Kelly Santos
Isis Kelly Santos
Ricardo CobucciRicardo Cobucci
Ricardo Cobucci
Objective: This meta-analysis of randomized controlled trials (RCTs) aimed to update evidence on the effectiveness and safety of laser therapy for treating genitourinary syndrome of menopause (GSM). Data sources: Manuscripts published until May 2023 were systematically searched in PubMed; Embase; Scopus; Web of Science; CENTRAL; CINAHL; and clinical trial databases (www.trialscentral.org, www.controlled-trials.com, and clinicaltrials.gov), […] Abstract Objective: This meta-analysis of randomized controlled trials (RCTs) aimed to update evidence on the effectiveness and safety of laser therapy for treating genitourinary syndrome of menopause (GSM). Data sources: Manuscripts published until May 2023 were systematically searched in PubMed; Embase; Scopus; Web of Science; CENTRAL; CINAHL; and clinical trial databases (www.trialscentral.org, www.controlled-trials.com, and clinicaltrials.gov), […]

1 January 2021 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
KMKleyton Santos de Medeiros
Kleyton Santos de Medeiros
LSLuís Antônio Soares da Silva
Luís Antônio Soares da Silva
LMLuíza Thomé de Araújo Macêdo
Luíza Thomé de Araújo Macêdo
ASAyane Cristine Alves Sarmento
Ayane Cristine Alves Sarmento
ACAna Paula Ferreira Costa
Ana Paula Ferreira Costa
AGAna Katherine Da Silveira Gonçalves
Ana Katherine Da Silveira Gonçalves
BACKGROUND: Although much has been studied about the SARS-Cov-2 virus, its effects, and the effectiveness of possible treatments, little is known about its interaction with other infectious diseases. OBJECTIVE: The aim is to study its clinical features and morbidity, and mortality outcomes of COVID-19 patients with HIV/AIDS coinfection. DATA SOURCES: MEDLINE, Web of Science, Embase, CINAHL, LILACS, Scopus, ClinicalTrials.gov, and Cochrane. STUDY ELIGIBILITY CRITERIA: Atudies in any language, published after 2019, were describing COVID-19 patients with HIV/AIDS. STUDY APPRAISAL: JBI Levels of Evidence, Joanna Briggs Institute. SYNTHESIS METHODS: As shown in the PRISMA flow diagram, two authors separately screened the search results from the obtained titles and abstracts. RESULTS: Chest CT was observed in patients with pneumonia by SARS-CoV-2 with findings of multiple ground-glass opacities (GGO) in the lungs, there is a need for supplemental oxygenation. One patient developed encephalopathy and complicated tonic-clonic seizures; four patients were transplanted (two, liver; two, kidneys), one patient developed severe SARS-CoV-2 pneumonia and 30 patients died (mortality rate, 11%). CONCLUSION: HIV did not show any relevance directly with the occurrence of COVID-19. Some studies suggest that HIV-1 infection through induction levels of IFN-I, may to some extent, stop the apparent SARS-CoV-2 infection, thus leading to undetectable RNA. Moreover, some authors suggest retroviral therapy routinely used to control HIV infection could be used to prevent COVID-19 infection.